"Our vaccine is quite effective in adolescents." :Moderna
On Tuesday, vaccine manufacturer Moderna announced that its COVID-19 vaccine (mRNA 1273) is 100 percent effective in preventing symptomatic infections in 12-17 year olds after two doses, increasing the likelihood of children returning to normal life in the United States. In early June, the company said it would approach the Food and Drug Administration (FDA) to request that its vaccine be extended to this age group.
Moderna CEO Stéphane Bancel said, "We are encouraged thatmRNA-1273 was highly effective at preventing Covid-19 in adolescents."
Some have criticised the United States for vaccinating children who are less prone to severe COVID-19 infections, whereas more vulnerable adult populations in countries around the world, including India, have yet to be vaccinated.
The Pfizer-BioNTech vaccine was recently approved for use in 12-15 years as an emergency vaccine.